References in periodicals archive ?
He received Simulect [R], an antibody to the interleukin-2 soluble receptor as an induction agent, as well as standard triple drug immunosuppression therapy based on tacrolimus, MMF, and prednisone.
Basiliximab (Simulect), a chimeric mouse-human monoclonal antibody, blocks the cellular receptor for the cytokine interleukin-2.
Basiliximab (Simulect) is a chimeric mouse-human monoclonal antibody that blocks the cellular receptor for the cytokine interleukin 2.
SangStat, Inc., Fremont, CA announced that an ad hoc independent Data Safety Monitoring Board (DSMB) decided to close the company's comparative kidney transplant study early after an interim analysis revealed significantly fewer rejections in patients treated the Thymoglobulin [Anti-thymocyte globulin, (Rabbit)] versus Novartis' Pharmaceutical's, East Hanover, NJ, Simulect (basiliximab).
Effect of "C2" cyclosporine levels and time to initiation of cyclosporine therapy on outcomes in patients receiving Neoral and Simulect [Abstract].
Novartis Pharmaceuticals, Inc., East Hanover, NJ, announced that severe acute hypersensitivity reactions, including anaphylaxis, have occurred in 17 patients receiving basiliximab (Simulect), a drug administered intravenously as a prophylaxis to prevent transplant rejection.
Novartis Pharma, AG, Basel, Switzerland, announced the scientific Body of the European Medicines Evaluation Agency, the Committee for Proprietary Medicinal Products (CPMP) has recommended extending the label for Simulect (basiliximab), a monoclonal antibody to prevent acute rejection in transplantation.
A multicenter pilot study of early (4 day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.
Novartis Pharmaceuticals, Inc., East Hanover, NJ, announced the Food and Drug Administration (FDA) has granted marketing clearance for Simulect (basiliximab) for prevention of acute rejections episodes in renal transplant recipients.
* MMF, Zenapax-MMF, Rapamycin-MMF, Myfortic in place of MMF, Simulect in place of Zenapax
The only Basiliximab product approved to be sold in China is Simulect, the brand-name drug by Novartis.
Patients in the BAS group received induction therapy with basiliximab (Simulect; Novartis, Basel, Switzerland) 20mg intravenously on day 0 intraoperatively after allograft reperfusion and on day 4 after LT.